HR 2715, the *Destruction of Hazardous Imports Act*, expands the authority to destroy imported goods that pose public health risks. It amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to order the destruction of any refused import (not just drugs or devices) if it presents a significant health concern. The bill also prohibits the unauthorized movement, sale, or export of such refused goods. These changes apply to importers of hazardous refused articles 180 days after enactment, with the FDA required to finalize implementing regulations within 90 days.
S 1022 amends Section 547 of the Public Health Service Act to increase annual funding for community recovery programs from $5 million to $16 million, covering fiscal years 2025-2029. It updates the program's name from "Building Communities of Recovery" to "Strengthening Communities of Recovery" and adjusts the funding period. This directly affects communities receiving federal support for substance use disorder recovery services under the Public Health Service Act.
The HEARD Act of 2025 directs the National Institutes of Health (NIH) to expand and coordinate research on rare diseases with a specific focus on health equity for minority populations. It requires NIH to establish a Coordinating Committee involving multiple federal agencies to develop a comprehensive plan for addressing rare diseases in minority communities, including research on epidemiology, diagnosis, and treatment. The bill creates new grant programs for data collection on rare diseases in minority populations, physician training programs on rare diseases, and scholarship/loan repayment programs for health professionals serving these communities, while also mandating reports to Congress on federal efforts to address these health disparities.
The Medical Supply Chain Resiliency Act (HR 2213) establishes a framework for the U.S. to form agreements with foreign countries that commit to reliable medical supply chains during emergencies. It allows the President to negotiate "trusted trade partner agreements" that reduce trade barriers (like duties and quotas) for medical goods with countries meeting specific criteria, such as maintaining open trade during health crises and protecting intellectual property. These agreements require Congressional review and approval, with ongoing monitoring to ensure partners uphold commitments. The bill directly affects U.S. trade policy, foreign governments seeking partnerships, and the medical supply industry by aiming to diversify sources and secure critical products like pharmaceuticals and medical devices.
The RAPID Reserve Act creates a federal program requiring drug manufacturers to maintain 6-month reserves of critical medicines with vulnerable supply chains - such as those concentrated in single regions or with few producers. Eligible manufacturers (with FDA-registered facilities and strong quality records) must store these reserves domestically or in OECD countries and share them during emergencies, like shortages or public health crises. The program prioritizes domestic production, allocates $500 million for fiscal year 2026, and mandates HHS to publish a list of covered drugs and report on the program’s effectiveness. It directly affects drug manufacturers and distributors selected to participate in the reserve system.
Skinny Labels, Big Savings Act This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs. Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. , a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics. The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act: submitting or seeking approval of a skinny label for a generic or biosimilar drug; promoting or commercially marketing a drug with skinny labeling approved by the FDA; or describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug. The bill also applies the safe harbor to similar actions under the Public Health Service Act.
This bill increases annual funding for community recovery programs under the Public Health Service Act from $5 million to $17 million per year, effective for fiscal years 2026 through 2030. It directly affects communities receiving federal support for substance use disorder and mental health services through existing grant programs. The key provision replaces previous funding levels (set for 2019-2023) with higher, extended funding for the next five years. This change provides greater financial support for local organizations addressing recovery needs without altering program requirements or eligibility.
The BITE Act establishes a national system to prevent diseases spread by ticks, mosquitoes, and fleas. It requires the Health Secretary to create a system with six key parts: a public vector identification service, an AI-powered early warning system using weather and habitat data, insurance claims monitoring for early outbreak detection, emergency room symptom tracking, targeted public education campaigns, and a goal to reduce Lyme disease by 25% by 2035. This system integrates human, animal, and environmental data (One Health approach) and serves both civilians and military medical facilities. The bill directly affects public health agencies, healthcare providers, and communities in areas with vector-borne diseases. Its key mechanism is using real-time data from multiple sources to predict and prevent disease outbreaks before they spread widely.
This bill establishes a federal interagency committee within NOAA to coordinate heat-health response across 15+ departments (including HHS, EPA, and FEMA) and requires a 5-year strategic plan to improve data sharing, research, and public communication about extreme heat. It creates the National Integrated Heat Health Information System (NIHHIS) to centralize heat-related data and forecasts, making it openly available for public use. The law mandates $5 million annually for 2025-2029 to fund these efforts, directly affecting federal agencies, state/local governments, Tribal nations, and communities facing heat risks. Key provisions include standardizing heat definitions, requiring agency coordination, and building public health preparedness tools to reduce heat-related illness and death.
The Domestic SUPPLY Act of 2025 establishes a federal program to ensure domestic production of personal protective equipment (PPE) for public health emergencies. It requires manufacturers partnering with the government to produce 50% of their PPE domestically by 2026, rising to 100% by 2028, be U.S.-owned, and meet CDC/OSHA safety standards. The bill also bans federal, state, and local governments from using public funds to buy foreign-made PPE for disease prevention after enactment, with limited exceptions requiring documentation. A report on PPE requirement changes since 2020 must be submitted to Congress within one year.
